Satellos Bioscience (NASDAQ:MSLE) Upgraded to Moderate Buy at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of Satellos Bioscience (NASDAQ:MSLE) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports.

MSLE has been the subject of several other reports. Leerink Partners assumed coverage on shares of Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Guggenheim assumed coverage on Satellos Bioscience in a report on Tuesday, April 28th. They set a “buy” rating and a $23.00 target price for the company. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Finally, Cantor Fitzgerald initiated coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Satellos Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Satellos Bioscience Trading Down 5.5%

NASDAQ:MSLE opened at $6.75 on Thursday. The business’s 50-day moving average price is $7.11. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39. The firm has a market capitalization of $140.60 million, a price-to-earnings ratio of -4.22 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). On average, equities analysts anticipate that Satellos Bioscience will post -2.26 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.